Lupin Limited has informed the Exchange regarding a press release dated September 03, 2025, titled "Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi s Long-Acting Injectable Platform".